Short answer
Lexeo Therapeutics, Inc. (LXEO) filed an 8-K current report with the SEC on September 22, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 1.01 (Entry into a Material Definitive Agreement), Item 8.01 (Other Events). Mantle acquisition consideration: $5.3M cash plus $3.0M Lexeo stock, subject to adjustments.
Lexeo Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Mantle acquisition consideration: $5.3M cash plus $3.0M Lexeo stock, subject to adjustments
- Up to $13.0M additional contingent consideration, including $1.0M cash and $12.0M milestone payments over 12 years
- Milestones tied to Mantle product development and regulatory achievements, with no guaranteed payments
- Key Mantle holders representing 76.1% of shares support approval, materially improving closing certainty
- Closing requires stockholder approval and other customary conditions, with termination permitted after November 16, 2026
Item 8.01 · Other Events
- Merger Agreement with Mantle Therapeutics and strategic collaborations mark a potentially transformative corporate development
- Expected merger closing and contingent consideration remain subject to conditions and execution risks
- CLARITY-FA study has 22 participants enrolled or imminently enrolling, advancing clinical development
- September 22 conference call and webcast provide management’s transaction rationale and business update
- Key risks include liquidity, clinical execution, regulatory approval, and uncertain translation from preclinical to clinical results
Item EX-99.1 · Exhibit EX-99.1
- Mantle acquisition adds four FA programs across oral, protein-replacement, and ASO modalities for $8.3M upfront
- Potential consideration reaches $21.3M, including $13.0M in success-based milestones
- LX3010 showed approximately 6-point mFARS improvement and nine-fold frataxin increase across 11 patients at 16 weeks
- Cash runway remains into 2028, including advancement of one acquired program; next FA IND targeted for 2027
- SUNRISE-FA 2 remains the top priority, with topline data expected in 2H 2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Lexeo Therapeutics, Inc. 8-K filings
Get the next LXEO 8-K as it lands
Follow LXEO for push alerts, or ask the research agent what this filing means.